MODELS AND METHODS IN MODERN SCIENCE
International scientific-online conference
168
QUANTITATIVE OF PLATELETS AGAINST THE BACKGROUND OF
ANTI-VIRUS THERAPY IN CHRONIC HEPATITIS WITH HCV
ETIOLOGY.
Nodira F. Nuriddinova
1
Zumrad Ch. Kurbonova
2
Dilafruz L. Zaynutdinova
3
1
Assistant, Department of Hematology, transfusiology and laboratory work,
Tashkent Medical Academy, E-mail: abdurahimnadi@gmail.com Tashkent,
Uzbekistan
2
Associate professor (DSc.), Department of Hematology, transfusiology and
laboratory work, Tashkent Medical Academy, E-mail:
zumradkurbonova3@gmail.com Tashkent, Uzbekistan
3
Assistant, Department of Hematology, transfusiology and laboratory work,
Tashkent Medical Academy, E-mail: dilafruzzaynutdinova00@gmail.com
Tashkent, Uzbekistan
https://doi.org/10.5281/zenodo.14195515
Background.
Liver disease leads to impaired blood clotting mainly due to
malfunction of platelet adhesion and aggregation. [7]. This dysfunction is related
to the activity of specific enzymes and transaminases in the liver [3,6]. An
increase in the activity of transaminases is a sign of cytolytic syndrome, in which
a decrease in platelet aggregation is observed [1.].
In the last decade, significant changes were noted in the laboratory
diagnosis of severe diffuse liver diseases associated with coagulation and
fibrinolysis systems. [2].
Aim.
The purpose of the study. Evaluation of the amount of platelets
against the background of antiviral therapy in chronic hepatitis of HCV etiology.
Material and methods.
The data were collected from patients treated
with HCV-etiological diseases hepatitis at the Department of Hematology and
Hepatobiliary Pathology of the 1st Clinic of the Tashkent Medical Academy in
2020-2023.
Results.
In 20 patients who did not receive antiviral therapy, the platelet
count was 216 ± 45 x109/l, while in 30 patients who received antiviral therapy,
the platelet count before treatment was 232 ± 50 x109/l, and after 1 month of
treatment, the platelet count was 221 ± 46 x109/l, after 3 months of treatment it
was equal to 203 ± 42 x109/l.
Conclusions.
In patients with chronic hepatitis of HCV etiology, the platelet
count was at the level of normal indicators, and in 30 patients with SGV of HCV
MODELS AND METHODS IN MODERN SCIENCE
International scientific-online conference
169
etiology, who received antiviral therapy, the platelet count did not reliably
change in patients who received AVT for 3 months.
List of references:
1.
Устинова М.Н. Агрегация тромбоцитов у больных хроническими
диффузными заболеваниями печени и ее коррекция внутривенной
озонотерапией: автореф. дис. кан. мед.наук. – Москва, 2005. –25 с
2.
Kurbonova Z.Ch. Features of hemostatic system disorders in patients with
chronic hepatitis and liver cirrhosis of viral etiology 14.00.29-Hematology and
transfusiology. Author's abstract. Tashkent – 2019. 45 p.
3.
Serov V.V., Bushueva N.V., Ignatova T.M., Aprosina Z.G. Viral and host
factors in the development and progression of chronic viral hepatitis C and B
//Russian Journal of Gastroenterology, Hepatology and Coloproctology.–2006.–
No. 4.–P.12–23.
4.
Caldwell S.H., Hoffman M., Lisman T.et al. Coagulation disorders and
hemostasis in liver disease: pathophysiology and critical assessment of current
management //Hepatology.–2006.–Vol.44.–P.44.
5.
Hollestelle M.J., Geertzen H.G.M., Straatsburg I.H., van Gulik T.M., van
Mourik J.A. Factor VIII expression in liver disease //Thromb Haemost.–2004.–
Vol.91,–P.267–275.
